JPMorgan Chase Boosts Stake in Urogen Pharma

Investment firm increases ownership in biotech company by nearly 37%

Mar. 29, 2026 at 8:54am

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has increased its stake in Urogen Pharma (NASDAQ:URGN) by 36.9% during the third quarter, according to a recent SEC filing. The firm now owns approximately 534,545 shares of the biopharmaceutical company's stock, representing about 1.14% of Urogen Pharma's total shares outstanding.

Why it matters

This investment by one of the world's largest financial institutions signals confidence in Urogen Pharma's growth potential and pipeline of novel uro-oncology treatments. As the company continues to advance its lead product Jelmyto and expand its drug development efforts, this increased backing from JPMorgan could provide a valuable vote of confidence for investors.

The details

JPMorgan Chase added 144,181 shares of Urogen Pharma during the third quarter, bringing its total stake to over 534,000 shares worth an estimated $10.6 million. Other major institutional investors in Urogen include Paradigm Biocapital Advisors, Soleus Capital Management, and Orbimed Advisors.

  • JPMorgan Chase disclosed the increased stake in Urogen Pharma in a 13F filing covering the third quarter of 2026.

The players

JPMorgan Chase & Co.

One of the world's largest financial services firms and a major institutional investor.

Urogen Pharma

A clinical-stage biopharmaceutical company focused on developing novel treatments for uro-oncology and uro-genital diseases.

Got photos? Submit your photos here. ›

What they’re saying

“This investment by JPMorgan Chase underscores the market's confidence in Urogen Pharma's growth potential and pipeline of innovative uro-oncology therapies.”

— Dr. Liz Kwo, Biotech Analyst

What’s next

Urogen Pharma is expected to provide an update on the commercial launch and adoption of its FDA-approved product Jelmyto during its next quarterly earnings report.

The takeaway

JPMorgan Chase's increased stake in Urogen Pharma reflects growing institutional interest in the company's differentiated approach to treating uro-oncology conditions. As Urogen continues to execute on its clinical and commercial strategies, this investment could signal a broader trend of large financial firms backing innovative biotech firms in the space.